RE:RE:Update on Phase II Bladder CancerI assume the update now includes the 6 patients they spoke of in recent email !
With the enrolment stage of our NMIBC only approximately 37 patients away and our results improving with every patient, we are very excited for the potential value of our share price.
Our clinical results are best in class and we are optimistic that this will be reflected in our future share price, rewarding our share holders.
Currently we are still waiting on 6 recently treated patients to be added to our results; we wouldn't be surprised with the news to come if positive, provides a significant lift to our share holders value.